Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2021-06-03 Director's Dealing
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-06-03 English
10-Q/A
Interim / Quarterly Report Q1 2021
2021-05-14 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated May 10, 2021, from Stoke Therapeutics, Inc. It announces the issuance of a press release regarding the company's financial results for the quarter ended March 31, 2021. The document itself does not contain detailed financial statements or substantive financial data but refers to the press release as an exhibit. The length of the document is 3701 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results, but the actual detailed financial data is in the attached press release. Given the short length and nature, it fits the Earnings Release category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2021-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about voting on board director elections and ratification of auditors, typical content for proxy solicitation materials. The text explicitly mentions 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and 'Definitive Additional Materials,' indicating it is related to proxy solicitation. It is not the actual Annual Report, nor an earnings release or other financial report. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 4155 characters, which is consistent with a proxy statement or related materials. Confidence is high due to clear identification of the SEC form and content.
2021-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.